Skip to main content

Hurvitz Chaim's Form 4/A amendment

Amended

NRX Pharmaceuticals, Inc. (NRXP) · filed Nov 23, 2022

Accession no.
0000950142-22-003250
Filed
Nov 23, 2022
Trade date
Oct 21-Nov 18, 2022
Filing delay
33 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Nov 21, 2022

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market purchases total $514.9K. It was filed 33 days after the trade.

This amendment replaces 0000950142-22-003233 (filed Nov 21, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hurvitz ChaimCIK 0001630542Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2022Common StockPPurchaseAcquired+287,812$0.99+$284,933.88287,812Direct
Nov 17, 2022Common StockPPurchaseAcquired+171,780$1.08+$185,522.4459,592Direct
Nov 18, 2022Common StockPPurchaseAcquired+40,408$1.10+$44,448.8500,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 21, 2022Common StockAGrant or awardAcquired+162,660––381,083Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)